Study S001669

The GLP-1 Agonist Semaglutide for the Treatment of Metabolic Disease in Liver Transplant Recipients: A Phase IV, Randomized Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05195944
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: ENROLLING_BY_INVITATION
Enrollment: 58
Start: 2022-10-26
Primary completion: 2026-12
Lead sponsor: University Health Network, Toronto
Conditions: Liver Transplant; Complications; Diabetes Mellitus; NASH - Nonalcoholic Steatohepatitis; NAFLD
Interventions: DRUG:Semaglutide Treatment; DRUG:Sitagliptin 100mg
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: REGISTRY:U1111-1268-1934

Registered primary outcomes

Change in HbA1c level [Baseline to 26 weeks]
Change in body weight (kg) [Baseline to week 26]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.